AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of drugs for ...
Tempus estimates that the net proceeds from the Offering will be approximately $384.1 million (or approximately $441.9 million if the initial purchasers exercise their option to purchase additional ...
7h
The Decision Crisis Inside Modern Business: Why Companies Have More Data Than Ever but Less Clarity
For decades, business leaders believed that better decisions would come from having more information. The logic seemed undeniable. More data meant greater visibility. Greater visibility meant stronger ...
Russia’s intensified drone attacks on small Ukrainian substations have severely disrupted the energy grid, causing $25B in ...
New Gemini shortcut: Typing '@' plus an app name in Google Gemini lets users access data or actions without opening the app separately. Workflow efficiency: The feature helps maintain focus by letting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results